Article Keyword Videos to Watch
Business
Click on the image to start the video.
|
Related Topics
Images - Links - Articles
Houston
Related Images
|
PPD Names Thomas Rosanske Executive Director of Product Development Analytical Services
WILMINGTON, N.C. (April 25, 2006) – PPD, Inc. (Nasdaq: PPDI) today announced Thomas Rosanske, Ph.D., has joined the company as executive director of product development analytical services for its cGMP laboratory.
Rosanske's responsibilities include strategic planning for the lab's core business of analytical method development, validation, stability and quality control testing. He will establish budgets and revenue forecasts as well as oversee approximately 180 staff. With extensive experience in pharmaceutics, Rosanske will establish pre-formulation and formulation development as new services offered by the lab.
"Tom brings more than 25 years of scientific, technical and regulatory experience," said Magdalena Mejillano, vice president of PPD's cGMP laboratory. "We expect his knowledge and expertise will enhance the value we provide our clients as we continue to expand our existing services and add new offerings."
Rosanske most recently served as executive director of pharmaceutical sciences at Beckloff Associates, Inc. Previously, he held senior research, regulatory and management positions at Eli Lilly and Company; Quintiles, Inc.; Hoechst Marion Roussel, Inc.; Marion Merrell Dow, Inc.; Marion Laboratories; and The Upjohn Company. Rosanske earned a bachelor's in chemistry from the University of Wisconsin-Oshkosh as well as a master's in analytical chemistry and a doctorate in pharmacy (pharmaceutics) from the University of Wisconsin-Madison. He currently holds an adjunct professorship appointment at the University of Kansas School of Pharmacy.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 27 countries and more than 8,400 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the anticipated value and contributions of the above-named employee and the prospects for our cGMP lab services business, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; competition within the outsourcing industry; rapid technological advances that make our products and services less competitive; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries; dependence on collaborative relationships; risks associated with acquisitions and investments; loss of large contracts; continued success in sales growth; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
About the Author: News brought to you by PPD, an international contract research organization specializing in clinical trial management for the pharmaceutical, biotechnology, and medical industries.
|
